Supriya Lifescience Ltd. (SLL) took another significant step on its ambitious growth trajectory with the inauguration of its new multi purpose Active Pharmaceutical Ingredients (APIs) production block, Module E, at the Lote Parshuram site. The facility, developed with an investment of approximately 125 crore, adds a substantial capacity of 335 kiloliters to the company's operations. This expansion boosts Lote Parshuram capacity by over 55%, increasing it from 597 KLPD to 932 KLPD.

The new production block is designed to support SLL's strategic focus on expanding its R&D capabilities and scaling up its pipeline of innovative products. Several new products in niche therapeutic areas are nearing the commercialization stage, reinforcing SLL's commitment to achieving a leadership position in these markets through efficient processes and backward integration. Some of the salient features of the facility are: .

The facility is tailored to support the company's backward integration model, ensuring economies of scale and a competive edge . Spread across 5,000 square meters and structured over four levels, the facility enables efficient operations and safe workflows . The facility houses 33 reactors, comprising stainless steel and glass-lined varieties, with capacities ranging from 1.6 KL to 16 KL .

The design leverages gravity-based process flows to enhance safety, maintain product integrity, and optimize efficiency . Incorporating closed-system handling at critical stages, the facility is equipped with process control automation systems and material handling systems to ensure compliance with the latest quality standards . The facility is equipped to handle a variety of unit processes and operations, making it adaptable to future needs.